OnKure Therapeutics (OKUR) vs. The Competition Head-To-Head Analysis

OnKure Therapeutics (NASDAQ:OKUR) is one of 1,045 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare OnKure Therapeutics to related businesses based on the strength of its valuation, profitability, dividends, institutional ownership, risk, earnings and analyst recommendations.

Risk & Volatility

OnKure Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, OnKure Therapeutics’ peers have a beta of 1.01, indicating that their average share price is 1% more volatile than the S&P 500.

Valuation & Earnings

This table compares OnKure Therapeutics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OnKure Therapeutics	N/A	-$77.39 million	-1.38
OnKure Therapeutics Competitors	$1.71 billion	$155.17 million	-5.62

OnKure Therapeutics’ peers have higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares OnKure Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-51.17%	-47.11%
OnKure Therapeutics Competitors	-3,615.52%	-270.14%	-30.84%

Insider & Institutional Ownership

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 44.4% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 17.9% of OnKure Therapeutics shares are owned by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations for OnKure Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	0	0	2	1	3.33
OnKure Therapeutics Competitors	7542	20748	48276	1179	2.55

OnKure Therapeutics presently has a consensus price target of $37.50, suggesting a potential upside of 122.16%. As a group, “Pharmaceutical preparations” companies have a potential upside of 66.46%. Given OnKure Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe OnKure Therapeutics is more favorable than its peers.

Summary

OnKure Therapeutics beats its peers on 9 of the 13 factors compared.

OnKure Therapeutics Company Profile

Reneo Pharmaceuticals Inc.is a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Inc.is based in SAN DIEGO.